Online inquiry

IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7969MR)

This product GTTS-WQ7969MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL7R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002185.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3575
UniProt ID P16871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7969MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12307MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ553MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ5600MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ13908MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ7444MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ8200MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ13246MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13253MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW